Loxo, Bayer get FDA okay for biomarker-driven cancer drug pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Lilly, preparing Alzheimer s drug plans, forms new neuroscience unit in company restructure biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.
Founder of Stamford-based Loxo Oncology launches another biotech firm
FacebookTwitterEmail
Dr. Joshua Bilenker, founder and then-CEO of Loxo Oncology, makes a point during an interview at the company’s main offices on Tresser Boulevard in downtown Stamford, Conn., on July 18, 2017.Michael Cummo / Hearst Connecticut Media
STAMFORD Dr. Josh Bilenker, the founder and former CEO of Stamford-based Loxo Oncology, one of the most influential cancer-focused startups of recent years, has launched another locally based oncology firm.
Treeline Biosciences aims to “prioritize molecular targets in oncology that are validated but difficult to drug” and “if successful, we believe that our approaches could apply to other therapeutic areas as well,” Bilenker and Treeline’s other founder, Dr. Jeff Engelman, wrote in a message posted on the firm’s website.